key: cord-0830926-0jbq03ru authors: Zhao, Dan; Xu, Weifan; Zhang, Xiaofan; Wang, Xiaoting; Yuan, Enming; Xiong, Yuanpeng; Wu, Shenyang; Li, Shuya; Wu, Nian; Tian, Tingzhong; Feng, Xiaolong; Shu, Hantao; Lang, Peng; Shen, Xiaokun; Li, Haitao; Li, Pilong; Zeng, Jianyang title: Understanding the phase separation characteristics of nucleocapsid protein provides a new therapeutic opportunity against SARS-CoV-2 date: 2020-10-09 journal: bioRxiv DOI: 10.1101/2020.10.09.332734 sha: 641c64839e4f2f0fc51b81bd21f414fe9a206d77 doc_id: 830926 cord_uid: 0jbq03ru The ongoing coronavirus disease 2019 (COVID-19) pandemic has raised an urgent need to develop effective therapeutics against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As a potential antiviral drug target, the nucleocapsid (N) protein of SARS-CoV-2 functions as a viral RNA chaperone and plays vital and multifunctional roles during the life cycle of coronavirus1-3. In this study, we discovered that the N protein of SARS-CoV-2 undergoes liquid-liquid phase separation (LLPS) both in vitro and in vivo, which is further modulated by viral RNA. In addition, we found that, the core component of the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, nsp12, preferentially partitions into the N protein condensates. Moreover, we revealed that, two small molecules, i.e., CVL218 and PJ34, can be used to intervene the N protein driven phase separation and loosen the compact structures of the condensates of the N-RNA-nsp12 complex of SARS-CoV-2. The discovery of the LLPS-mediated interplay between N protein and nsp12 and the corresponding modulating compounds illuminates a feasible way to improve the accessibility of antiviral drugs (e.g., remdesivir) to their targets (e.g., nsp12/RdRp), and thus may provide useful hints for further development of effective therapeutic strategies against SARS-CoV-2. To date, tens of millions of people have been infected with severe acute respiratory In recent years, liquid-liquid phase separation (LLPS) has been shown to offer a highly 64 efficient mechanism to spatially and temporally modulate the cellular processes, such In this study, we determined the unique characteristics of the phase separation driven 80 by the N protein of SARS-CoV-2 (termed SARS-CoV-2-N) both in vitro and in vivo. 81 The influence of individual protein domains, mutations and nucleic acids on the phase 82 condensation of SARS-CoV-2-N was also depicted. Importantly, the interplay between 94 The nucleocapsid (N) protein of SARS-CoV-2 (termed SARS-CoV-2-N), in common Confocal fluorescence microscopy showed that SARS-CoV-2-N readily self-associated 107 to form numerous micron-sized spherical condensates (Fig. 1b, c) . Further time-lapse 108 observations revealed that the SARS-CoV-2-N condensates fused and coalesced into Next, we examined whether SARS-CoV-2-N can also undergo LLPS in vivo, by 123 ectopically expressing an mCherry tagged version of SARS-CoV-2-N in cells. We 124 observed that SARS-CoV-2-N formed numerous puncta-like structures upon 125 expression in Vero E6 cells (Fig. 1g) . We further evaluated the dynamicity of SARS-126 CoV-2-N within these puncta using FRAP, and the spatiotemporal analysis of bleaching 127 events showed that SARS-CoV-2-N redistributed rapidly from the unbleached area to 128 the bleached one (Fig. 1g, h) . In addition, time-lapse observations revealed that the 129 SARS-CoV-2-N puncta fused into larger condensates right after their interactions ( Fig. 130 1i, Supplementary Video 2). All together, these results showed that SARS-CoV-2-N is 131 also able to undergo LLPS in vivo. In vitro phase separation assays of the Alx546-labeled wild-type (WT) N protein and four mutants 238 with mutations on the serine-arginine (SR) rich region with viral RNA of different concentrations. 239 The ratio of N protein to viral RNA was 1:1. Scale bar, 20 μm. including R203K, S194L, S197L, and S188L mutants (4 among the top 5 mutations) 266 (see Extended Data Fig. 2b) , and then examined their phase separation capacity. Interestingly, these mutants displayed markedly weaker phase separation than the wild-268 type N protein (Fig. 3e) . Thus, it is conceivable that the SR rich region acts as a and nsp8 together (Fig. 5a) . It was previously reported that N protein can cooperate 323 with RdRp to facilitate viral infection 25 . However, the underlying mechanisms still 324 remain largely obscure. To further explore whether the interplay between N protein and 325 RdRp of SARS-CoV-2 is mediated by phase separation, we also purified the nsp12 326 protein (see Extended Data Fig. 2c ) and examined its potential involvement in LLPS. 327 We observed that nsp12 alone cannot undergo phase separation under physiological salt 328 condition (Fig. 5b) , whereas it readily converted to amorphous condensates when can influence the morphology of the N protein driven condensates, and also augment 459 their sizes in vitro (Fig. 5f) . Meanwhile, we also observed an increasing number of 460 puncta of overexpressed mCherry-N in Vero-E6 cells, after CVL218/PJ34 treatment 461 (see Extended Data Fig. 6a, b) . In addition, these two small molecules both tune the small-molecule drugs into the condensates. Therefore, we propose that CVL218 or PJ34 468 can be applied to facilitate the entrance of other antiviral drugs (e.g., remdesivir 51-53 ) 469 into RTCs by remodeling the communications between N protein and RTCs and 470 promoting the permeability of RTCs (Fig. 5i) . Our results suggest that the N protein For the control wells, cell medium containing 1% DMSO was added. Imaging was 544 performed with a NIKON A1 microscope equipped with a 100× oil immersion objective. NIS-Elements AR Analysis was used to analyze the images. Properties of Coronavirus and SARS-CoV-2 The SARS coronavirus 599 nucleocapsid protein--forms and functions The SARS-CoV nucleocapsid protein: a protein with multifarious 602 activities Recent insights into the development of 604 therapeutics against coronavirus diseases by targeting N protein Structural basis for the identification of the N-terminal domain of coronavirus 607 nucleocapsid protein as an antiviral target A data-driven drug repositioning framework discovered a potential therapeutic 610 agent targeting COVID-19. bioRxiv In-silico homology assisted identification of inhibitor of RNA binding against 612 2019-nCoV N-protein (N terminal domain) Phase transitions in the assembly of multivalent signalling proteins Stoichiometry controls activity of phase-617 separated clusters of actin signaling proteins Transcription Factors Activate Genes through the Phase-Separation Capacity of 620 Coactivator condensation at super-enhancers links phase separation and gene 624 control Organization of Chromatin by Intrinsic and Regulated Phase Separation Liquid droplet formation by HP1 alpha suggests a role for phase separation 629 in heterochromatin Functional Characterization of Negri Bodies (NBs) in Rabies Virus-Infected 631 Cells: Evidence that NBs Are Sites of Viral Transcription and Replication Induction of Stress Granule-Like Structures in Vesicular Stomatitis Virus-634 Infected Cells Negri bodies are viral factories with properties of liquid organelles Measles Virus Forms Inclusion Bodies with 639 Properties of Liquid Organelles Drive the Formation of Vesicular Stomatitis Virus Replication Compartments Phase Separation of Epstein-Barr Virus EBNA2 and Its Coactivator EBNALP 646 Fine Structure of Cellular 649 Inclusions in Experimental Measles Inclusion Bodies Are a Site of Ebolavirus Replication Virus factories, double membrane vesicles and viroplasm 654 generated in animal cells Virus factories: associations of cell organelles for viral replication and 656 morphogenesis Nucleocapsid Protein Recruitment to Replication-Transcription Complexes Plays 658 a Crucial Role in Coronaviral Life Cycle Dynamics of coronavirus replication-transcription complexes The coronavirus nucleocapsid protein is dynamically associated with the 662 replication-transcription complexes Analyzing Protein Disorder with IUPred2A IUPred2A: context-dependent prediction of protein 666 disorder as a function of redox state and protein binding PLAAC: a web and command-669 line application to identify proteins with prion-like amino acid composition The disordered P granule protein LAF-1 drives phase separation into 672 droplets with tunable viscosity and dynamics Phase transition of a disordered nuage protein generates environmentally 675 responsive membraneless organelles A Molecular Grammar Governing the Driving Forces for Phase Separation of 678 A systematic survey identifies 681 prions and illuminates sequence features of prionogenic proteins Specific Interaction between Coronavirus Leader Rna and Nucleocapsid High affinity interaction between nucleocapsid 686 protein and leader/intergenic sequence of mouse hepatitis virus RNA RNA-Induced Conformational Switching and Clustering of G3BP Drive 689 Stress Granule Assembly by Condensation MUSCLE: multiple sequence alignment with high accuracy and high throughput The 2019 novel coronavirus resource Variant analysis of SARS-CoV-2 genomes The establishment of reference sequence for SARS-CoV-2 and variation analysis Nucleocapsid phosphorylation and RNA helicase DDX1 700 recruitment enables coronavirus transition from discontinuous to continuous transcription Glycogen synthase kinase-3 regulates the phosphorylation of severe acute 703 respiratory syndrome coronavirus nucleocapsid protein and viral replication Phosphorylation modulates liquid-liquid phase separation of the SARS-706 Phosphorylation of the arginine/serine dipeptide-rich motif 708 of the severe acute respiratory syndrome coronavirus nucleocapsid protein modulates its 709 multimerization, translation inhibitory activity and cellular localization Architecture and self-assembly of the SARS-712 CoV-2 nucleocapsid protein Nucleocapsid protein of SARS-CoV-2 phase separates into RNA-rich 714 polymerase-containing condensates. bioRxiv SARS-CoV-2 nucleocapsid protein undergoes liquid-liquid phase 716 separation stimulated by RNA and partitions into phases of human ribonucleoproteins. bioRxiv Specific viral RNA drives the SARS CoV-2 nucleocapsid to phase separate Partitioning of cancer therapeutics in nuclear condensates Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is 723 Mediated by the Viral Polymerase and the Proofreading Exoribonuclease Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA 726 polymerase from severe acute respiratory syndrome coronavirus 2 with high potency Structural basis for inhibition of the RNA-dependent RNA polymerase from 729 SARS-CoV-2 by remdesivir Rapid review for the anti-coronavirus effect of remdesivir SARS-CoV-2 and COVID-19 Structure of the RNA-dependent RNA polymerase from COVID-19 virus